MediGene: Presentation of EndoTAG(TM)-1 and oHSV Results at the 2009 ASCO Annual Meeting

Martinsried/Munich, May 26, 2009. The biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announces that final clinical data obtained with the drug candidate EndoTAG(TM)-1 will be presented at a poster discussion at the 2009 ASCO Annual Meeting (American Society of Clinical Oncology) in Orlando. Professor Matthias Löhr, principal investigator of the phase II clinical trial of EndoTAG(TM)-1 for the treatment of inoperable pancreatic carcinoma, will present the results from this trial, which were published in October 2008. Matthias Löhr is professor of gastroenterology and hepatology at  Karolinska Institutet, Stockholm, and Head of Molecular Gastroenterology at the German Cancer Research Center (DKFZ), Heidelberg. The selection of the EndoTAG(TM)-1 data for presentation at the ASCO Annual Meeting illustrates the great interest in this drug candidate on the part of scientists. The poster is titled "Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: a phase II trial", and will be presented on Sunday, May 31, 2009 at 2.00 p.m. - 6.00 p.m. local time (11.00 .p.m. CEST) (abstract no. 4526). 




Moreover the data obtained in the clinical trial of the oncolytic virus NV1020 in patients with colorectal cancer and liver metastases, as well as final data from a trial of the oncolytic virus G207 for the treatment of malignant brain tumors will be presented during two poster sessions. The posters are titled "Phase II efficacy results using an onkolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC)" (abstract no. 4089), and "Treatment of recurrent malignant glioma with G207. A genetically engineered herpes simplex virus-1, followed by irradiation: phase I study results" (abstract no. 2042). Both posters will be presented on Sunday, May 31, 2009 from 8.00 - 12.00 a.m. local time (5.00 p.m. CEST).




This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGene(TM) and EndoTAG(TM) are trademarks of MediGene AG. This trademark may be held or licensed for specific countries.




- ends -




MediGene AG is a publicly listed (Frankfurt: MDG, Prime Standard, TecDAX) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market, which are being distributed by partner companies and has several drug candidates in clinical development, two of which provide significant sales potential. In addition, the company has numerous projects in research and pre-clinical development and possesses innovative platform technologies. MediGene focuses on the research and development of novel drugs for the treatment of cancer and autoimmune diseases




Contact MediGene AG




Fax: +49 - 89 - 85 65 - 2920


Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: +49 - 89 - 85 65 - 3324


Dr. Georg Dönges, Investor Relations, Tel.: +49 - 89 - 85 65 - 2946